Opportunity Information: Apply for PAR 15 314
Apply for PAR 15 314
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Discovery of Genetic Basis of Monogenic Heart, Lung, Blood, and Sleep Disorders (X01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.837 Cardiovascular Diseases Research 93.838 Lung Diseases Research 93.839 Blood Diseases and Resources Research.
- This funding opportunity was created on Jul 29, 2015 and posted on Jul 29, 2015.
- Applicants must submit their applications by Jun 15, 2018. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 20 candidate(s).
- Eligible applicants include: Independent school districts For profit organizations other than small businesses County governments Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Public and State controlled institutions of higher education Special district governments City or township governments Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments Native American tribal governments (Federally recognized).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity "Discovery of Genetic Basis of Monogenic Heart, Lung, Blood, and Sleep Disorders (X01)" (Funding Opportunity Number PAR-15-314) is a National Institutes of Health (NIH) program designed to help researchers identify the genetic causes of Mendelian (single-gene) disorders that have a meaningful impact on heart, lung, blood, and sleep (HLBS) systems. The central idea is to connect investigators who have well-characterized patients and families affected by suspected monogenic HLBS conditions with a major national sequencing resource, the Centers for Mendelian Genomics (CMGs). Rather than funding a traditional, stand-alone research project with an investigator building sequencing infrastructure locally, this FOA emphasizes leveraging the CMGs' genome-wide sequencing capacity to accelerate gene discovery, clarify disease mechanisms, and improve the understanding of rare inherited HLBS disorders.
The funding instrument type is a grant, and the mechanism is an X01, which is generally used by NIH to provide access to specific research resources rather than primarily supplying large amounts of direct research dollars. In practical terms, the value for applicants is the ability to use high-throughput genome-wide sequencing and associated analytic expertise available through the CMGs to pursue the genetic basis of a monogenic disorder. Projects under this opportunity would typically involve recruiting or assembling appropriate case material (often families, trios, or multiple affected individuals), providing strong phenotypic characterization, and then applying genome-wide approaches (such as whole-exome or whole-genome sequencing) to identify candidate variants and genes responsible for disease.
This FOA sits within NIH's health research mission areas that map directly to HLBS topics, as reflected by the CFDA program areas listed: 93.837 (Cardiovascular Diseases Research), 93.838 (Lung Diseases Research), and 93.839 (Blood Diseases and Resources Research). The announcement anticipated up to 20 awards, indicating a moderate-sized cohort of supported projects, likely reflecting the capacity limits of the CMGs and the desire to select projects with a high probability of yielding interpretable gene discoveries. There is no cost-sharing or matching requirement, which lowers barriers for institutions that may not have discretionary funds to meet a matching obligation.
Eligibility under this FOA is broad and spans a wide range of organizational types. Eligible applicants include public and private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status, with some distinctions), for-profit organizations other than small businesses, small businesses, and multiple levels of government (state, county, city/township, special district). The eligibility language also explicitly includes groups and institution types such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribal Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), and faith-based or community-based organizations. It also allows certain non-U.S. entities (foreign organizations), regional organizations, U.S. territories or possessions, and eligible federal agencies, reflecting NIH's interest in capturing rare disorders and informative families wherever they may be found, while still operating within NIH policy constraints.
Key timing details show the FOA was posted and created on July 29, 2015, with an original and final closing date of June 15, 2018, and an archive date of July 16, 2018. That means the opportunity is no longer open for new submissions, but the description remains useful for understanding how NIH structured access to CMG sequencing resources for Mendelian HLBS gene discovery during that period, and it can serve as a model for similar resource-access announcements.
The administering agency is NIH, and the official announcement page (historical reference) is provided through the NIH grants guide at http://grants.nih.gov/grants/guide/pa-files/PAR-15-314.html. For access or technical issues with the full announcement, the contact listed is the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV, which is a standard help contact for linking or document access problems.
Overall, this FOA is best understood as an NIH-supported pathway for investigators working on rare, likely single-gene HLBS disorders to obtain genome-wide sequencing and analysis support through a specialized national consortium (the CMGs). The program focus is on discovering or confirming disease genes and variants, using carefully phenotyped Mendelian cases to generate findings that can deepen biological understanding and, over time, support better diagnostics and potentially inform therapeutic research for rare but often severe inherited HLBS conditions.
Frequently Asked Questions (FAQs)
What is the "Discovery of Genetic Basis of Monogenic Heart, Lung, Blood, and Sleep Disorders (X01)" opportunity?
It is an NIH funding opportunity (Funding Opportunity Number PAR-15-314) focused on identifying the genetic causes of Mendelian (single-gene) disorders that affect heart, lung, blood, and sleep (HLBS) systems. The program is designed to accelerate gene discovery for rare inherited HLBS conditions by connecting qualified investigators with a national sequencing resource.
What does "monogenic" or "Mendelian" mean in this announcement?
In this context, "monogenic" (or "Mendelian") refers to disorders that are suspected to be caused primarily by a change in a single gene and that often show inheritance patterns consistent with Mendelian genetics in families.
What is the main goal of this FOA?
The central goal is to discover or confirm disease-causing genes and variants for suspected monogenic HLBS disorders by using genome-wide sequencing and analytic expertise provided through the Centers for Mendelian Genomics (CMGs).
What is the X01 mechanism and what does it typically provide?
The mechanism is an X01, which NIH generally uses to provide access to specific research resources rather than primarily providing large amounts of direct research dollars. Under this FOA, the key value is access to high-throughput genome-wide sequencing capacity and associated analytic expertise through the CMGs.
What are the Centers for Mendelian Genomics (CMGs) and what role do they play here?
The CMGs are described as a major national sequencing resource. Under this FOA, they provide genome-wide sequencing and analysis support to help identify candidate variants and genes responsible for Mendelian disorders affecting HLBS systems.
How is this different from a traditional research grant?
Instead of supporting an investigator to build or rely on local sequencing infrastructure as part of a stand-alone project, this FOA emphasizes leveraging the CMGs' established sequencing and analysis capabilities to speed up gene discovery for rare HLBS disorders.
What kinds of research activities or projects were expected under this FOA?
Projects were typically expected to involve assembling appropriate case material (often families, trios, or multiple affected individuals), providing strong phenotypic characterization, and using genome-wide approaches such as whole-exome sequencing or whole-genome sequencing to identify candidate disease-causing variants and genes.
What types of patient or family data were considered important for applications?
Applicants were expected to have well-characterized patients and families affected by suspected monogenic HLBS conditions, with strong phenotypic characterization and informative case material such as families, trios, or multiple affected individuals.
Which disease areas does this opportunity cover?
The focus is on heart, lung, blood, and sleep (HLBS) systems, specifically rare inherited disorders that are likely single-gene in origin and have meaningful HLBS impact.
Which NIH program areas (CFDA numbers) are associated with this FOA?
The FOA maps to NIH program areas reflected by the listed CFDA numbers: 93.837 (Cardiovascular Diseases Research), 93.838 (Lung Diseases Research), and 93.839 (Blood Diseases and Resources Research).
How many awards were anticipated?
The announcement anticipated up to 20 awards, suggesting a moderate-sized cohort aligned with the CMGs' capacity and the intent to select projects with strong potential for interpretable gene discoveries.
Was cost-sharing or matching required?
No. The FOA states there was no cost-sharing or matching requirement.
Who was eligible to apply?
Eligibility was broad and included public and private institutions of higher education; nonprofit organizations (including those with and without 501(c)(3) status, with some distinctions); for-profit organizations other than small businesses; small businesses; and multiple levels of government (state, county, city/township, special district).
Did the FOA encourage applications from specific institution types (for example, minority-serving institutions)?
Yes. The eligibility language explicitly included Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribal Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), and faith-based or community-based organizations.
Were non-U.S. organizations allowed to apply?
Yes. The eligibility language included certain non-U.S. entities (foreign organizations), regional organizations, and also included U.S. territories or possessions and eligible federal agencies, reflecting interest in capturing rare disorders and informative families wherever they may be found while operating within NIH policy constraints.
When was this FOA posted and what were the closing dates?
The FOA was posted/created on July 29, 2015. The original and final closing date was June 15, 2018. The archive date was July 16, 2018.
Is this funding opportunity still open?
No. Based on the listed final closing date (June 15, 2018) and archive date (July 16, 2018), it is no longer open for new submissions.
What agency administered this opportunity?
The administering agency was the National Institutes of Health (NIH).
Where can I find the official FOA announcement page?
The historical NIH Grants Guide announcement page is: http://grants.nih.gov/grants/guide/pa-files/PAR-15-314.html
Who was listed as the contact for technical issues accessing the announcement?
For access or technical issues with the full announcement, the contact listed was the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
What is the overall purpose of connecting investigators to the CMGs?
The program is intended to speed discovery or confirmation of disease genes and variants for rare, likely single-gene HLBS disorders by pairing well-phenotyped Mendelian cases with specialized national sequencing and analysis support, ultimately improving understanding of disease mechanisms and supporting progress in diagnostics and future research directions.
Browse more opportunities from the same category: Health
Next opportunity: Sitka Youth Expedition to Glacier Bay (Find Your Parks)
Previous opportunity: National Park Service National Historic Landmark Nomination, Pan American Union
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 15 314
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 15 314) also looked into and applied for these:
| Funding Opportunity |
|---|
| Substance Abuse Service Expansion Apply for HRSA 16 074 Funding Number: HRSA 16 074 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Limited Competition for the Renewal of the National Cell Repository of Alzheimers Disease (NCRAD) (U24) Apply for PAR 15 316 Funding Number: PAR 15 316 Agency: National Institutes of Health Category: Health Funding Amount: $900,000 |
| Support for Activities to Eradicate Polio, Accelerate control of measles and rubella Apply for CDC RFA GH13 130204CONT16 Funding Number: CDC RFA GH13 130204CONT16 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Emerging Infections ProgramNational Center for Emerging and Zoonotic Infectious Diseases Apply for CDC RFA CK12 120205CONT16 Funding Number: CDC RFA CK12 120205CONT16 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Poliomyelitis Eradication Initiative and Expanded Programme On Immunization Apply for CDC RFA GH13 130104CONT16 Funding Number: CDC RFA GH13 130104CONT16 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Enhancing Public Health Surveillance of Autism Spectrum Disorders and Other Developmental Disabilities through the Autism and Developmental Disabilities Monitoring (ADDM) Network Apply for CDC RFA DD15 150102CONT16 Funding Number: CDC RFA DD15 150102CONT16 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| National HIV Surveillance System (NHSS) Apply for CDC RFA PS13 13020401SUPP16 Funding Number: CDC RFA PS13 13020401SUPP16 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $120,000 |
| AHRQ Grants for Health Services Research Dissertation Program (R36) Apply for PA 15 318 Funding Number: PA 15 318 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Tuskegee University Apology Commemoration Activities Apply for CDC RFA PS15 150402CONT16 Funding Number: CDC RFA PS15 150402CONT16 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| NIMHD Transdisciplinary Collaborative Centers for Health Disparities Research on Chronic Disease Prevention (U54) Apply for RFA MD 15 014 Funding Number: RFA MD 15 014 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| U.S. India Collaborative Vision Research Program (R01) Apply for PAR 15 320 Funding Number: PAR 15 320 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Pilot Services Research Grants Not Involving Interventions (R34) Apply for PAR 15 323 Funding Number: PAR 15 323 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Special Diabetes Program for Indians Community Directed Program Apply for HHS 2016 IHS SDPI 0001 Funding Number: HHS 2016 IHS SDPI 0001 Agency: Indian Health Service Category: Health Funding Amount: $6,500,000 |
| Alzheimers Disease Core Centers (P30) Apply for RFA AG 16 018 Funding Number: RFA AG 16 018 Agency: National Institutes of Health Category: Health Funding Amount: $900,000 |
| Minority HIV/AIDS Research Initiative (MARI) to Build HIV Prevention, Treatment and Research Capacity in Apply for RFA PS 16 001 Funding Number: RFA PS 16 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| Building Genomic Sequencing Capacity in Kenya Apply for CDC RFA GH15 1636 Funding Number: CDC RFA GH15 1636 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Ethical, Legal and Policy Issues in HIV Research with Key Populations (R21) Apply for PAR 15 327 Funding Number: PAR 15 327 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Oral HIVacc Oral Mucosal Immunization Approaches for HIV Prevention (R01) Apply for RFA DE 16 006 Funding Number: RFA DE 16 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Ethical, Legal and Policy Issues in HIV Research with Key Populations (R01) Apply for PAR 15 328 Funding Number: PAR 15 328 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| A National Coalition to Enhance STD/HIV Prevention through Promotion of a Holistic Approach to Health and Wellness Apply for CDC RFA PS11 111205CONT15 Funding Number: CDC RFA PS11 111205CONT15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 15 314", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.